You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Potent inhibitor of noradrenalin and dopamine uptake (Ki values are 4.7, 26 and 4000 nM for inhibition of noradrenalin, dopamine and 5-HT uptake respectively, in rat brain). Increases central dopamine levels in rats following systemic administration. Displays antidepressant activity.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 354.4. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.82 mL||14.11 mL||28.22 mL|
|5 mM||0.56 mL||2.82 mL||5.64 mL|
|10 mM||0.28 mL||1.41 mL||2.82 mL|
|50 mM||0.06 mL||0.28 mL||0.56 mL|
References are publications that support the biological activity of the product.
Tuomisto (1977) Nomifensine and its derivatives as possible tools for studying amine uptake. Eur.J.Pharmacol. 42 101 PMID: 844493
Nakachi et al (1995) Effects of various DA uptake inhibitors on striatal extracellular DA levels and behaviours in rats. Eur.J.Pharmacol. 281 195 PMID: 7589207
Katz et al (2010) Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons. J.Psychopharmacol. 24 1223 PMID: 19939862
If you know of a relevant reference for Nomifensine, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Nomifensine, Nomifensine supplier, noradrenaline, noradrenalin, norepinephrine, NET, DAT, transporter, transports, dopamine, reuptake, uptake, inhibitors, inhibits, antidepressants, anti-depressants, Adrenergic, Transporters, Dopamine, 1992, Tocris Bioscience
1 Citation for Nomifensine
Citations are publications that use Tocris products. Selected citations for Nomifensine include:
Zapata et al (2007) Regulation of DA transporter function and cell surface expression by D3 DA receptors. J Biol Chem 282 35842 PMID: 17923483
Do you know of a great paper that uses Nomifensine from Tocris? Please let us know.
Reviews for Nomifensine
There are currently no reviews for this product. Be the first to review Nomifensine and earn rewards!
Have you used Nomifensine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.